Form 4: Design Therapeutics Director Sells 3,806 Shares at $6.27

A Design Therapeutics director, Deepa Prasad, sold 3,806 shares of common stock at a price of $6.27 per share on December 18, 2024.

Summary

• Deepa Prasad, a director at Design Therapeutics, sold 3,806 shares of the company's common stock on December 18, 2024.
• The sale was executed at a price of $6.27 per share.
• Following the transaction, Ms. Prasad directly owns 20,000 shares of Design Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing for an insider stock sale, which is neither positive nor negative in itself. It's a neutral event.

Industry Context

This is a routine SEC Form 4 filing, which is common for corporate insiders who trade company stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for publicly traded companies in the United States.
• The sale of shares by a director is a common occurrence and does not necessarily indicate a negative outlook for the company.
• Similar filings are made by directors and officers of all publicly traded companies, such as those in the biotechnology sector like BioMarin Pharmaceutical or Vertex Pharmaceuticals.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on investor sentiment, but is unlikely to have a significant impact on the company's operations or financial health.

Key Dates

Keywords

Design Therapeutics, DSGN, insider trading, stock sale, Deepa Prasad, director